SCHEMBL4467294

SCHEMBL4467294

Cc1ccc(CO)cc1-n1c(C)cc(O)cc1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
EPHB4 P54760 2/20 0.40
LMNA P02545 2/20 0.36
ALDH1A1 P00352 3/20 0.35
APEX1 P27695 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TYR P14679 1/20 0.33
IDH1 O75874 3/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
CASP1 P29466 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ACHE P22303 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
APLNR P35414 1/20 0.32
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
LCK P06239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4381315 0.86 POLB (0.40) POLBLMNAALDH1A1TYRIDH1
SCHEMBL4389841 0.86 POLB (0.40) POLBLMNAALDH1A1L3MBTL1TYR
SCHEMBL4373994 0.77 POLB (0.41) POLBLMNAALDH1A1TDP1L3MBTL1
SCHEMBL4380038 0.73 MAPK14 (0.49)
SCHEMBL2706645 0.73 ALDH1A1 (0.60) POLBLMNAALDH1A1APEX1TDP1
SCHEMBL12798350 0.73 MAPK14 (0.48) POLBALDH1A1APEX1TDP1L3MBTL1
SCHEMBL6471875 0.70 ALDH1A1 (0.56) POLBLMNAALDH1A1APEX1TDP1
SCHEMBL13610554 0.70 HSP90AB1 (0.47) POLBLMNAALDH1A1L3MBTL1KDM4E
SCHEMBL18799989 0.70 POLB (0.40) POLBLMNAAPLNR
SCHEMBL4374369 0.70 NPSR1 (0.42) POLBLMNAALDH1A1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 POLB 1610/4885EPHB4 1641/4885LMNA 1815/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 POLB 1676/4885EPHB4 1348/4885LMNA 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.